Recombinant hepatocyte growth factor treatment in a canine model of congenital liver hypoplasia
Article first published online: 29 MAR 2011
© 2011 John Wiley & Sons A/S
Volume 31, Issue 7, pages 940–949, August 2011
How to Cite
Kruitwagen, H. S., Arends, B., Spee, B., Brinkhof, B., van den Ingh, T. S.G.A.M., Rutten, V. P.M.G., Penning, L. C., Roskams, T. and Rothuizen, J. (2011), Recombinant hepatocyte growth factor treatment in a canine model of congenital liver hypoplasia. Liver International, 31: 940–949. doi: 10.1111/j.1478-3231.2011.02513.x
- Issue published online: 6 JUL 2011
- Article first published online: 29 MAR 2011
- Received 28 October 2010, Accepted 24 February 2011
- liver hypoplasia;
- liver regeneration;
Background: Although the liver has a large regenerative capacity, in many hepatopathies, these repair mechanisms fail. The therapeutic potential of hepatocyte growth factor (HGF) has been proven in numerous toxin-induced liver failure models in rodents, but never in spontaneously occurring liver diseases in larger animal models.
Aim: The aim of this study was to induce liver growth in a hypoplastic liver by the administration of exogenous recombinant HGF. The natural hypoplastic liver model used is the canine congenital portosystemic shunt (CPSS) characterized by strongly reduced liver growth and function.
Methods: Recombinant HGF (rHGF), 200 μg/kg, was given twice daily during 3 weeks by an intravenous injection in six dogs with CPSS. Liver volumes were determined by computed tomography before and at 1, 2, 3 and 7 weeks after the initiation of treatment. Portosystemic shunting was evaluated with an ammonia tolerance test and liver portal perfusion was quantified with scintigraphy. Simultaneously, blood parameters for liver function were assayed and liver biopsies were taken for histology, immunohistochemistry and gene-expression measurements.
Results: During 3 weeks of HGF treatment, hepatocyte proliferation increased and an increase in liver volume up to 44% was seen, persisting in two dogs up to 4 weeks after the termination of treatment. Ki-67 expression, gene expression of E2F1 and CDC6, phosphorylated-c-MET and phosphorylated-ERK1/2 protein levels confirmed increased hepatocyte proliferation and HGF signalling. The aberrant portal perfusion did not change during treatment.
Conclusions: Transient in vivo liver growth is shown using CPPS as a naturally occurring large animal model, indicating the therapeutic potential of HGF in liver disease.